+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Fluorine-18 fluorodeoxyglucose positron emission tomography in the staging and follow-up of lymphoma: is it time to shift gears?



Fluorine-18 fluorodeoxyglucose positron emission tomography in the staging and follow-up of lymphoma: is it time to shift gears?



European Journal of Nuclear Medicine 27(10): 1564-1578



Positron emission tomography (PET) imaging has become a very useful technique for staging and monitoring therapy response in lymphoma, providing unique information about the biological behavior of disease. Increased fluorine-18 fluorodeoxyglucose (FDG) uptake in lymphoma is based on elevated glycolysis and longer residence time of FDG in malignant cells compared with most normal tissues. The metabolic information provided by this technique suggests that FDG-PET may be more sensitive than the anatomical imaging modalities. Computed tomography (CT) is the principal imaging modality for the staging and restaging of lymphoma. Nonetheless, this technique has significant shortcomings, particularly in the post-therapy setting. Gallium-67 scintigraphy has played an important role in monitoring response to therapy and follow-up of patients; however, the sensitivity of 67Ga depends on the subtype of lymphoma and the size and location of disease. Published results strongly indicate that FDG-PET is superior to 67Ga imaging and may be equal or superior to CT for the detection of nodal as well as extranodal involvement in lymphoma.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 046106953

Download citation: RISBibTeXText

PMID: 11083548

DOI: 10.1007/s002590000340


Related references

Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and Gallium-67 scintigraphy in staging and follow-up of patients with lymphoma. Blood 94(10 Suppl. 1 Part 1): 84a, 1999

Role of attenuation correction for fluorine-18 fluorodeoxyglucose positron emission tomography in the primary staging of malignant lymphoma. European Journal of Nuclear Medicine 26(1): 31-38, 1999

Performance of Positron Emission Tomography and Positron Emission Tomography/Computed Tomography Using Fluorine-18-Fluorodeoxyglucose for the Diagnosis, Staging, and Recurrence Assessment of Bone Sarcoma: A Systematic Review and Meta-Analysis. Medicine 94(36): E1462, 2015

Positron emission tomography with 18-fluorodeoxyglucose in the staging and follow-up of lymphoma in the chest. Acta Oncologica 38(6): 799-804, 1999

Positron Emission Tomography with 18-F-Fluorodeoxyglucose in the Staging and Follow-Up of Lymphoma: Status quo and quo vadis. Onkologie 22(5): 382-386, 1999

Unilateral primary adrenal natural killer/T-cell lymphoma: Role of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography for staging and interim response assessment. Indian Journal of Nuclear Medicine 31(1): 52-54, 2016

Pre-transplant positron emission tomography/computed tomography (PET/CT) in relapsed Hodgkin lymphoma: time to shift gears for PET-positive patients?. Leukemia and Lymphoma 52(9): 1615-1616, 2011

Paget's disease of pelvis mimicking metastasis in a patient with lung cancer evaluated using staging and follow-up imaging with fluorine-18 fluorodeoxyglucose-positron emission tomography/computed tomography. Indian Journal of Nuclear Medicine 30(2): 151-153, 2015

F-Fluorodeoxyglucose Positron Emission Tomography ( 18 F-Fdg-Pet) for Staging and Follow-Up of Marginal Zone B-Cell Lymphoma. Oncology 64(4): 336-340, 2003

18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET) for staging and follow-up of marginal zone B-cell lymphoma. Oncology 64(4): 336-340, 2003

Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography with gallium-67 scintigraphy in the initial clinical staging of diffuse large B-cell lymphoma. International Journal of Hematology 107(2): 194-200, 2018

Extending positron emission tomography scan utility to high-risk neuroblastoma: fluorine-18 fluorodeoxyglucose positron emission tomography as sole imaging modality in follow-up of patients. Journal of Clinical Oncology 19(14): 3397-3405, 2001

Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin's disease and non-Hodgkin's lymphoma. American Journal of Medicine 112(4): 262-268, 2002

Can fluorodeoxyglucose positron emission tomography/computed tomography avoid negative iliac crest biopsies in evaluation of marrow involvement by lymphoma at time of initial staging?. Leukemia and Lymphoma 52(11): 2111-2116, 2011

Fluorine-18 fluorodeoxyglucose-positron emission tomography in the initial staging of sinonasal malignancy. 2013